Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain
NCT00410787
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Analgesics, Opioid
Pain
Interventions
DRUG:
OROS hydromorphone HCI (slow release)
Sponsor
Alza Corporation, DE, USA